Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
News and updates for 908 Devices Inc. (NASDAQ: MASS) center on its development and deployment of purpose-built handheld devices for chemical analysis in health, safety and defense technology applications. The company reports that its tools are used at the point of need to interrogate unknown and invisible materials and provide quick, actionable answers in situations involving drugs, toxic chemicals and security threats.
Investors and observers following 908 Devices can expect regular news on quarterly financial results, including revenue from product sales, service and contract revenue, recurring revenue tied to its installed base, and non-GAAP measures such as adjusted gross margin and adjusted EBITDA. These updates are often accompanied by commentary on channel mix, recurring revenue trends and strategic focus on handheld chemical analysis tools.
The company also issues news about product developments and launches. Recent announcements describe handheld analyzers that combine FTIR and Raman spectroscopy through proprietary Smart Spectral Processing algorithms, as well as devices designed for rapid field-based identification of unknown bulk solids, liquids, gases and vapors. Such releases highlight capabilities like trace-level detection of drugs, explosives and hazardous materials, wireless connectivity and integration with the 908 Devices Team Leader app.
Another key theme in 908 Devices’ news flow is adoption by government and defense organizations. Public updates have detailed purchases of handheld mass spectrometry and gas identification devices by entities such as the United States Coast Guard and United States Marine Corps for narcotics interdiction, hazardous threat detection and protection of installations and coastal communities.
Corporate governance and investor relations activities also appear in the news stream, including participation in investor conferences, webcasts of earnings calls and changes to the Board of Directors that align with the company’s focus on public health, safety and defense tech. For a comprehensive view of how 908 Devices is executing its strategy, readers can review this evolving news record over time.
908 Devices has secured significant contracts to supply advanced chemical detection devices to the European Union's rescEU disaster preparedness initiative. The company has delivered 108 devices to EU member states over the past six months.
Key deployments include:
- Czech Fire Brigade: 6 MX908 mass spectrometry devices for Q2 2025, adding to their existing 12 devices (XplorIR and ThreatID)
- Finland: 90 ProtectIR handheld FTIR analyzers, delivered across Q4 2024 and Q1 2025
These devices enhance disaster response capabilities by enabling rapid identification of chemical, biological, radiation, and nuclear (CBRN) threats. The MX908 can detect hazardous substances in multiple forms, while ProtectIR can identify over 23,000 chemical substances.
908 Devices (Nasdaq: MASS) has received a $2 million order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This follows an initial order from last year and is funded through the Community Oriented Policing Services (COPS) grant.
The MX908 devices, shipped in April, will be deployed throughout Texas at critical interdiction locations. The technology enables first responders to detect and identify trace amounts of hazardous substances, including synthetic opioids like fentanyl and nitazenes, and counterfeit pills.
The investment comes amid rising fentanyl-related deaths in Texas, which have increased by 158% from 2020 to 2023. The devices will support agencies including the Criminal Investigations Division and Narcotics Enforcement in modernizing frontline detection capabilities to combat the opioid crisis.
908 Devices (Nasdaq: MASS) reported preliminary Q1 2025 financial results, showing strong revenue growth of 55% from continuing operations, reaching at least $11.5 million compared to $7.4 million in Q1 2024. The company recently divested its desktop portfolio, generating an additional $1.1 million in revenue that will be reported under discontinued operations.
The company maintains a strong financial position with approximately $124 million in cash, cash equivalents, and marketable securities, plus $4.0 million held in escrow from the desktop portfolio divestiture. Following this strategic move, 908 Devices is focusing on its advanced chemical detection strategy, with management reaffirming their commitment to achieving Adjusted EBITDA positivity by Q4 2025.
908 Devices (Nasdaq: MASS) has secured a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module, scheduled for priority shipment in Q1 2025.
The MX908 devices, featuring proprietary High Pressure Mass Spectrometry (HPMS) technology, will be integrated into environmental testing kits for post-war applications. The system is designed to detect and identify trace levels of hazardous materials, including explosives, chemical agents, and priority drugs.
The Aero module enhancement enables rapid detection of aerosolized threats, including chemical warfare agents, pharmaceutical-based agents, and opioid analogs, providing first responders with critical actionable information for public safety.
908 Devices (NASDAQ: MASS) announced a strategic transformation and Q4/FY2024 financial results. The company divested its desktop portfolio to Repligen for $70 million, strengthening its focus on handheld chemical analysis devices.
Key financial highlights include:
- Q4 2024 revenue: $18.8M (+31% YoY)
- Full year 2024 revenue: $59.6M (+19% YoY)
- Handheld revenue: $46.1M (+22% YoY)
- Recurring revenue: $23.3M (39% of total revenue)
The company expects 11-15% revenue growth in 2025, with anticipated acceleration above 20% in 2026. The transformation reduces headcount by 33%, eliminates $20M in annual operating losses, and aims to achieve Adjusted EBITDA positivity by Q4 2025 and cash flow positivity in 2026. Gross margins are projected to reach mid-to-high 50% range in 2025.
Repligen (RGEN) has acquired the desktop bioprocessing analytics portfolio from 908 Devices (MASS) for $70 million in cash. The acquisition includes four PAT (Process Analytical Technology) devices: MAVERICK, MAVEN, REBEL, and ZipChip.
The acquired technologies enable real-time monitoring, control of bioprocess parameters, cell culture media analysis, and high-resolution sample separations for product quality characterization. This strategic move strengthens Repligen's PAT portfolio and expands its capabilities across the entire bioprocess workflow.
Following the transaction, 908 Devices will focus on growing its handheld device portfolio for health and safety applications. The deal includes the transfer of 908's bioprocessing team to Repligen.
908 Devices (Nasdaq: MASS), a pioneer in handheld and desktop chemical analysis devices, has announced its participation in two major investor conferences. The company will be featured in:
- A fireside chat at the TD Cowen 45th Annual Healthcare Conference in Boston on March 5 at 9:50 a.m. Eastern Time
- A fireside chat at the Leerink Global Healthcare Conference in Miami on March 11 at 1:00 p.m. Eastern Time
Investors and interested parties can access live and archived webcasts of both sessions through the company's investor relations website at www.908devices.com.
908 Devices (Nasdaq: MASS), a pioneer in handheld and desktop chemical analysis devices, has scheduled its fourth quarter and full year 2024 financial results announcement for March 4, 2025, before market open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results. Investors can access the live audio webcast through the company's website investor section, with a replay available within 24 hours after the event.
908 Devices (Nasdaq: MASS) announced preliminary unaudited financial results for Q4 and full year 2024. Q4 revenue is expected to reach $17.2 million, up 20% from $14.4 million in Q4 2023. Full-year 2024 revenue is anticipated at $58.0 million, showing 15% growth compared to $50.2 million in 2023, meeting the high end of revenue guidance.
Both handheld and desktop revenues showed double-digit growth year-over-year in Q4, with desktop revenues also growing sequentially. The RedWave Technology acquisition, completed in April 2024, is expected to meet its post-acquisition revenue target of $11 million for approximately 8 months of ownership, delivering double-digit pro-forma growth. The company consumed about $2 million in cash during Q4, ending with $69.5 million in cash, cash equivalents, and marketable securities.
908 Devices (Nasdaq: MASS) and Getinge have announced a partnership to integrate their technologies for enhanced bioreactor monitoring. The collaboration combines Getinge's bioreactors with 908 Devices' MAVEN system for automated control of glucose and lactate levels in cell cultures.
The integrated solution enables continuous, real-time analysis without manual sampling, allowing biopharma scientists to maintain optimal nutrient concentrations. MAVEN can monitor up to two bioreactors simultaneously, with data being managed through Getinge's advanced controllers. The system will be compatible with Getinge's Livit Flex controller and connected through Livit Links sensor ports.